mRNAワクチン医薬品開発サービスの世界市場規模、シェア、企業ランキング、売上、需要動向予測（2026～2032年）

mRNA Vaccine Drugs Development Services - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032

レポートID：
97224
発表時期：
2026-01-14
レポート形式：
PDF
産業カテゴリー：
ソフト及び商業サービス
レポート言語：
英語、日本語
ページ数：
112
発行会社（調査会社）：
QYResearch

レポートの概要

本報告書は、世界のmRNAワクチン医薬品開発サービス市場について包括的な分析を行い、市場全体の動向を明らかにすることを目的としています。売上高に加え、主要企業の市場シェアおよび順位を整理し、市場構造を多角的に把握します。さらに、地域・国別、製品タイプ別、用途分野別などの観点からmRNAワクチン医薬品開発サービス市場を分析し、需要構造と成長特性を明確化します。
mRNAワクチン医薬品開発サービス市場の規模、推定値および予測は、2025年を基準年とし、2021年から2032年までの期間における売上高に基づいて提示しています。定量分析と定性分析を組み合わせることで、ビジネスおよび成長戦略を検討し、市場競争環境を評価し、企業の市場ポジションを把握した上で、mRNAワクチン医薬品開発サービスに関する的確な意思決定を行うための実践的なインサイトを提供します。

 主要mRNAワクチン医薬品開発サービス市場の統計
2025年世界市場規模：百万米ドル
2026年世界市場規模：百万米ドル
2032年予測市場規模：百万米ドル
2026–2032年予測期間CAGR：
本レポートはmRNAワクチン医薬品開発サービス市場の中長期的な成長動向を定量分析および定性分析の両面から体系的に整理しています。 
【市場セグメンテーション】
主要企業・競争環境
mRNAワクチン医薬品開発サービス市場の主要企業には以下が含まれます：
ReciBioPharm
Merck
Samsung Biologics
Thermo Fisher Scientific
Lonza
Ricoh Group
Aldevron
Wuxi Biologics
Genscript Probio
Novoprotein
Porton Advanced Solutions
Precision NanoSystems 

製品別
mRNA Process Development Services
mRNA Synthesis Services
mRNA Drug Substance Purification Services
Others 

アプリケーション別
Non-Replicating mRNA Vaccine Drugs
Self-Amplifying mRNA Vaccine Drugs 

レポート対象地域
北米：アメリカ、カナダ、その他
アジア太平洋：中国、日本、韓国、東南アジア、インド、オーストラリア、その他
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、オランダ、北欧諸国、その他
ラテンアメリカ：メキシコ、ブラジル、その他
中東・アフリカ：トルコ、サウジアラビア、UAE、その他
レポート構成（章別概要）
第1章｜市場概要と成長展望
mRNAワクチン医薬品開発サービス市場の全体像を整理し、市場規模、売上予測を体系的に解説します。同時に成長要因、市場機会、業界課題、リスク要因を分析し、中長期的な市場展望を提示します
第2章｜主要企業の競争分析
mRNAワクチン医薬品開発サービス市場における主要プレイヤー（トップ5社・トップ10社）を対象に、売上高、製造拠点、製品構成、市場シェアを多面的に分析し、競争構造を明確化します
第3章｜製品カテゴリ別市場動向
製品タイプ別にmRNAワクチン医薬品開発サービス市場を分類し、売上高、市場シェアを分析します。成長性の高い製品分野と市場構造の変化を明らかにします
第4章｜用途別市場動向
用途別にmRNAワクチン医薬品開発サービス市場規模、売上高、市場シェアを整理し、業界別の需要動向と成長ポテンシャルを分析します
第5章｜地域別市場分析
地域別の市場成長率、売上高を詳細に分析し、mRNAワクチン医薬品開発サービス市場の地理的需要構造を可視化します。各地域の市場規模推移と将来の成長余地を評価します。
第6章｜国別市場動向
主要国・地域ごとに、mRNAワクチン医薬品開発サービス市場の売上高、成長要因、政策・規制環境、競争特性を整理し、国別市場の特徴を明確にします
第7章｜主要企業プロファイル
mRNAワクチン医薬品開発サービス市場を牽引する主要企業について、売上高、粗利益率、製品ポートフォリオ、最新の戦略動向を詳細に解説します
第8章｜バリューチェーンと市場構造分析
業界全体のサプライチェーンを上流から下流まで整理し、コスト構造や流通モデルの動向を分析します
第9章｜調査結果
調査結果を総括し、市場全体のトレンド、今後の成長機会、潜在的リスク、戦略的な洞察を提示します
第10章｜付録（調査手法・データソース）
調査設計、分析手法、使用データソースの詳細を明示し、レポートの信頼性と透明性を担保します

本レポートの要点と洞察
●mRNAワクチン医薬品開発サービス市場の全体像と成長見通し
mRNAワクチン医薬品開発サービス市場の規模変化の傾向、成長予測及び需要動向を体系的に整理いたします。2021年から2025年までの実績データに基づき、2032年までの中長期予測を提示し、市場の拡大速度と成長潜在力を明らかにします。同時に、最近の関税調整措置など各国の政策動向を踏まえ、多角的にグローバル経済環境がmRNAワクチン医薬品開発サービス市場に与える影響を分析いたします。
●市場環境の構成要素とマクロトレンド
mRNAワクチン医薬品開発サービス産業を取り巻く市場環境について、需要構造の変化、政策対応、技術革新の進展といった主要要因を整理します。特に、国際貿易政策や関税政策の変化が企業戦略に及ぼす影響、サプライチェーン再編の動きと事業運営への波及効果を明確化し、市場環境の全体像を包括的に提示します。
●競争構造と主要企業の動向分析
mRNAワクチン医薬品開発サービス市場における主要企業の売上規模、市場シェア、競争ポジションを整理し、競争構造の特徴を分析します。各社の競争戦略、事業拡大の方向性、新製品・新技術の投入動向を通じて、技術革新が市場競争に与える影響と競争環境の変化を解読します。
●競争環境と事業動向の把握
製品タイプ別、用途別、地域・国別の観点からmRNAワクチン医薬品開発サービス市場のセグメント構造を整理します。各地域の需要構成と成長特性を比較分析し、各細分領域が市場全体の成長に与える貢献度と相互関連性を明確にします。
●成長要因・課題・リスクの分析
mRNAワクチン医薬品開発サービス市場の成長を支える主要ドライバーを整理するとともに、業界特有の課題や潜在的リスクを分析します。原材料調達、供給システム、事業運営における不確実性を踏まえ、サプライチェーン及び事業レジリエンス強化の方向性についても考察します。
●将来トレンドと市場展望
mRNAワクチン医薬品開発サービス市場の中長期的な成長トレンドと将来の発展シナリオを提示します。持続的成長を実現するための重要な成功要因を整理し、今後の市場参入企業や既存プレイヤーの戦略的意思決定に参考となる視点を提供いたします。

Description

The global market for mRNA Vaccine Drugs Development Services was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.

mRNA vaccine drug development services refer to providing comprehensive and professional technical support and services for the research, development and production of mRNA vaccines. This kind of service covers the research and development and design of mRNA vaccines, production process optimization, quality control, preclinical and clinical research and other aspects. By using advanced mRNA technology and platform-based production processes, we can quickly respond to the threats of various infectious diseases and develop efficient and safe mRNA vaccines. At the same time, the mRNA vaccine drug development service also has strong data analysis capabilities and clinical trial experience, which can provide scientific basis and decision-making support for vaccine research and development. This kind of service is widely used in the field of public health and is of great significance to protecting human health and promoting social development.

The North American market for mRNA Vaccine Drugs Development Services was valued at US$ million in 2025 and is projected to reach US$ million by 2032, at a CAGR of % from 2026 to 2032.

The Asia-Pacific market for mRNA Vaccine Drugs Development Services was valued at $ million in 2025 and is projected to climb to US$ million by 2032, at a CAGR of % from 2026 to 2032.

The European market for mRNA Vaccine Drugs Development Services was valued at $ million in 2025 and is projected to total US$ million by 2032, at a CAGR of % from 2026 to 2032.

The global key companies in the mRNA Vaccine Drugs Development Services market include ReciBioPharm、Merck、Samsung Biologics、Thermo Fisher Scientific、Lonza、Ricoh Group、Aldevron、Wuxi Biologics、Genscript Probio、Novoprotein, etc. In 2025, the five largest players accounted for approximately % of revenue.

This report provides a comprehensive view of the global market for mRNA Vaccine Drugs Development Services, covering total sales revenue, the market share and ranking of key companies, along with analyses by region & country, by Type, and by Application.

The mRNA Vaccine Drugs Development Services market size, estimations, and forecasts are presented in terms of sales revenue ($ millions), with 2025 as the base year and historical and forecast data from 2021 to 2032. The report combines quantitative and qualitative analysis to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current marketplace, and make informed business decisions regarding mRNA Vaccine Drugs Development Services.

Market Segmentation
By Company
    ReciBioPharm
    Merck
    Samsung Biologics
    Thermo Fisher Scientific
    Lonza
    Ricoh Group
    Aldevron
    Wuxi Biologics
    Genscript Probio
    Novoprotein
    Porton Advanced Solutions
    Precision NanoSystems

Segment by Type
    mRNA Process Development Services
    mRNA Synthesis Services
    mRNA Drug Substance Purification Services
    Others

Segment by Application
    Non-Replicating mRNA Vaccine Drugs
    Self-Amplifying mRNA Vaccine Drugs

By Region
    North America
    Europe
    Asia-Pacific
    Latin America
    Middle East & Africa

Consumption by Region
    North America
        United States
        Canada
    Asia-Pacific
        China
        Japan
        South Korea
        Southeast Asia
        India
        Australia
        Rest of Asia-Pacific
    Europe
        Germany
        France
        U.K.
        Italy
        Netherlands
        Nordic Countries
        Rest of Europe
    Latin America
        Mexico
        Brazil
        Rest of Latin America
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE
        Rest of MEA

Chapter Outline
Chapter 1: Introduces the scope of the report and the global market size (value). It also summarizes market dynamics and recent developments; identifies key drivers and restraints; outlines challenges and risks for players; reviews relevant industry policies.
Chapter 2: Provides a detailed analysis of the mRNA Vaccine Drugs Development Services companies' competitive landscape—including revenue shares, recent development plans, and mergers and acquisitions (M&A).
Chapter 3: Analyzes market segmentation by Type, presenting the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 4: Analyzes market segmentation by Application, presenting the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 5: Presents mRNA Vaccine Drugs Development Services revenue at the regional level. It offers a quantitative assessment of market size and growth potential by region and summarizes market development, future prospects, addressable space, and country-level market size worldwide.
Chapter 6: Presents mRNA Vaccine Drugs Development Services revenue at the country level. It provides segmented data by Type and by Application for each country/region.
Chapter 7: Profiles key players, detailing the main companies' product revenue, gross margin, product portfolios, recent developments, etc.
Chapter 8: Analysis of Value Chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Table of Contents

1 Market Overview
    1.1 mRNA Vaccine Drugs Development Services Product Introduction
    1.2 Global mRNA Vaccine Drugs Development Services Market Size Forecast (2021–2032)
    1.3 mRNA Vaccine Drugs Development Services Market Trends & Drivers
        1.3.1 mRNA Vaccine Drugs Development Services Industry Trends
        1.3.2 mRNA Vaccine Drugs Development Services Market Drivers & Opportunities
        1.3.3 mRNA Vaccine Drugs Development Services Market Challenges
        1.3.4 mRNA Vaccine Drugs Development Services Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

2 Competitive Analysis by Company
    2.1 Global mRNA Vaccine Drugs Development Services Players Revenue Ranking (2025)
    2.2 Global mRNA Vaccine Drugs Development Services Revenue by Company (2021–2026)
    2.3 Key Companies’ R&D and Operations Footprint and Headquarters
    2.4 Key Companies mRNA Vaccine Drugs Development Services Product Offerings
    2.5 Key Companies General Availability (GA) Timeline for mRNA Vaccine Drugs Development Services
    2.6 mRNA Vaccine Drugs Development Services Market Competitive Analysis
        2.6.1 mRNA Vaccine Drugs Development Services Market Concentration Rate (2021–2026)
        2.6.2 Top 5 and Top 10 Global Companies by mRNA Vaccine Drugs Development Services Revenue in 2025
        2.6.3 Global Companies by Tier (Tier 1, Tier 2, Tier 3), based on mRNA Vaccine Drugs Development Services revenue, 2025
    2.7 Mergers & Acquisitions and Expansion

3 Segmentation mRNA Vaccine Drugs Development Services Market Classification
    3.1 Introduction by Type
        3.1.1 mRNA Process Development Services
        3.1.2 mRNA Synthesis Services
        3.1.3 mRNA Drug Substance Purification Services
        3.1.4 Others
        3.1.5 Global mRNA Vaccine Drugs Development Services Sales Value by Type
            3.1.5.1 Global mRNA Vaccine Drugs Development Services Sales Value by Type (2021 vs 2025 vs 2032)
            3.1.5.2 Global mRNA Vaccine Drugs Development Services Sales Value, by Type (2021–2032)
            3.1.5.3 Global mRNA Vaccine Drugs Development Services Sales Value, by Type (%), 2021–2032

4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Non-Replicating mRNA Vaccine Drugs
        4.1.2 Self-Amplifying mRNA Vaccine Drugs
    4.2 Global mRNA Vaccine Drugs Development Services Sales Value by Application
        4.2.1 Global mRNA Vaccine Drugs Development Services Sales Value by Application (2021 vs 2025 vs 2032)
        4.2.2 Global mRNA Vaccine Drugs Development Services Sales Value by Application (2021–2032)
        4.2.3 Global mRNA Vaccine Drugs Development Services Sales Value by Application (%), 2021–2032

5 Segmentation by Region
    5.1 Global mRNA Vaccine Drugs Development Services Sales Value by Region
        5.1.1 Global mRNA Vaccine Drugs Development Services Sales Value by Region: 2021 vs 2025 vs 2032
        5.1.2 Global mRNA Vaccine Drugs Development Services Sales Value by Region (2021–2026)
        5.1.3 Global mRNA Vaccine Drugs Development Services Sales Value by Region (2027–2032)
        5.1.4 Global mRNA Vaccine Drugs Development Services Sales Value by Region (%), 2021–2032
    5.2 North America
        5.2.1 North America mRNA Vaccine Drugs Development Services Sales Value, 2021–2032
        5.2.2 North America mRNA Vaccine Drugs Development Services Sales Value by Country (%), 2025 vs 2032
    5.3 Europe
        5.3.1 Europe mRNA Vaccine Drugs Development Services Sales Value, 2021–2032
        5.3.2 Europe mRNA Vaccine Drugs Development Services Sales Value by Country (%), 2025 vs 2032
    5.4 Asia Pacific
        5.4.1 Asia Pacific mRNA Vaccine Drugs Development Services Sales Value, 2021–2032
        5.4.2 Asia Pacific mRNA Vaccine Drugs Development Services Sales Value by Subregion (%), 2025 vs 2032
    5.5 South America
        5.5.1 South America mRNA Vaccine Drugs Development Services Sales Value, 2021–2032
        5.5.2 South America mRNA Vaccine Drugs Development Services Sales Value by Country (%), 2025 vs 2032
    5.6 Middle East & Africa
        5.6.1 Middle East & Africa mRNA Vaccine Drugs Development Services Sales Value, 2021–2032
        5.6.2 Middle East & Africa mRNA Vaccine Drugs Development Services Sales Value by Country (%), 2025 vs 2032

6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions mRNA Vaccine Drugs Development Services Sales Value Growth Trends, 2021 vs 2025 vs 2032
    6.2 Key Countries/Regions mRNA Vaccine Drugs Development Services Sales Value, 2021–2032
    6.3 United States
        6.3.1 United States mRNA Vaccine Drugs Development Services Sales Value, 2021–2032
        6.3.2 United States mRNA Vaccine Drugs Development Services Sales Value by Type (%), 2025 vs 2032
        6.3.3 United States mRNA Vaccine Drugs Development Services Sales Value by Application, 2025 vs 2032
    6.4 Europe
        6.4.1 Europe mRNA Vaccine Drugs Development Services Sales Value, 2021–2032
        6.4.2 Europe mRNA Vaccine Drugs Development Services Sales Value by Type (%), 2025 vs 2032
        6.4.3 Europe mRNA Vaccine Drugs Development Services Sales Value by Application, 2025 vs 2032
    6.5 China
        6.5.1 China mRNA Vaccine Drugs Development Services Sales Value, 2021–2032
        6.5.2 China mRNA Vaccine Drugs Development Services Sales Value by Type (%), 2025 vs 2032
        6.5.3 China mRNA Vaccine Drugs Development Services Sales Value by Application, 2025 vs 2032
    6.6 Japan
        6.6.1 Japan mRNA Vaccine Drugs Development Services Sales Value, 2021–2032
        6.6.2 Japan mRNA Vaccine Drugs Development Services Sales Value by Type (%), 2025 vs 2032
        6.6.3 Japan mRNA Vaccine Drugs Development Services Sales Value by Application, 2025 vs 2032
    6.7 South Korea
        6.7.1 South Korea mRNA Vaccine Drugs Development Services Sales Value, 2021–2032
        6.7.2 South Korea mRNA Vaccine Drugs Development Services Sales Value by Type (%), 2025 vs 2032
        6.7.3 South Korea mRNA Vaccine Drugs Development Services Sales Value by Application, 2025 vs 2032
    6.8 Southeast Asia
        6.8.1 Southeast Asia mRNA Vaccine Drugs Development Services Sales Value, 2021–2032
        6.8.2 Southeast Asia mRNA Vaccine Drugs Development Services Sales Value by Type (%), 2025 vs 2032
        6.8.3 Southeast Asia mRNA Vaccine Drugs Development Services Sales Value by Application, 2025 vs 2032
    6.9 India
        6.9.1 India mRNA Vaccine Drugs Development Services Sales Value, 2021–2032
        6.9.2 India mRNA Vaccine Drugs Development Services Sales Value by Type (%), 2025 vs 2032
        6.9.3 India mRNA Vaccine Drugs Development Services Sales Value by Application, 2025 vs 2032

7 Company Profiles
    7.1 ReciBioPharm
        7.1.1 ReciBioPharm Profile
        7.1.2 ReciBioPharm Main Business
        7.1.3 ReciBioPharm mRNA Vaccine Drugs Development Services Products, Services, and Solutions
        7.1.4 ReciBioPharm mRNA Vaccine Drugs Development Services Revenue (US$ Million), 2021–2026
        7.1.5 ReciBioPharm Recent Developments
    7.2 Merck
        7.2.1 Merck Profile
        7.2.2 Merck Main Business
        7.2.3 Merck mRNA Vaccine Drugs Development Services Products, Services, and Solutions
        7.2.4 Merck mRNA Vaccine Drugs Development Services Revenue (US$ Million), 2021–2026
        7.2.5 Merck Recent Developments
    7.3 Samsung Biologics
        7.3.1 Samsung Biologics Profile
        7.3.2 Samsung Biologics Main Business
        7.3.3 Samsung Biologics mRNA Vaccine Drugs Development Services Products, Services, and Solutions
        7.3.4 Samsung Biologics mRNA Vaccine Drugs Development Services Revenue (US$ Million), 2021–2026
        7.3.5 Samsung Biologics Recent Developments
    7.4 Thermo Fisher Scientific
        7.4.1 Thermo Fisher Scientific Profile
        7.4.2 Thermo Fisher Scientific Main Business
        7.4.3 Thermo Fisher Scientific mRNA Vaccine Drugs Development Services Products, Services, and Solutions
        7.4.4 Thermo Fisher Scientific mRNA Vaccine Drugs Development Services Revenue (US$ Million), 2021–2026
        7.4.5 Thermo Fisher Scientific Recent Developments
    7.5 Lonza
        7.5.1 Lonza Profile
        7.5.2 Lonza Main Business
        7.5.3 Lonza mRNA Vaccine Drugs Development Services Products, Services, and Solutions
        7.5.4 Lonza mRNA Vaccine Drugs Development Services Revenue (US$ Million), 2021–2026
        7.5.5 Lonza Recent Developments
    7.6 Ricoh Group
        7.6.1 Ricoh Group Profile
        7.6.2 Ricoh Group Main Business
        7.6.3 Ricoh Group mRNA Vaccine Drugs Development Services Products, Services, and Solutions
        7.6.4 Ricoh Group mRNA Vaccine Drugs Development Services Revenue (US$ Million), 2021–2026
        7.6.5 Ricoh Group Recent Developments
    7.7 Aldevron
        7.7.1 Aldevron Profile
        7.7.2 Aldevron Main Business
        7.7.3 Aldevron mRNA Vaccine Drugs Development Services Products, Services, and Solutions
        7.7.4 Aldevron mRNA Vaccine Drugs Development Services Revenue (US$ Million), 2021–2026
        7.7.5 Aldevron Recent Developments
    7.8 Wuxi Biologics
        7.8.1 Wuxi Biologics Profile
        7.8.2 Wuxi Biologics Main Business
        7.8.3 Wuxi Biologics mRNA Vaccine Drugs Development Services Products, Services, and Solutions
        7.8.4 Wuxi Biologics mRNA Vaccine Drugs Development Services Revenue (US$ Million), 2021–2026
        7.8.5 Wuxi Biologics Recent Developments
    7.9 Genscript Probio
        7.9.1 Genscript Probio Profile
        7.9.2 Genscript Probio Main Business
        7.9.3 Genscript Probio mRNA Vaccine Drugs Development Services Products, Services, and Solutions
        7.9.4 Genscript Probio mRNA Vaccine Drugs Development Services Revenue (US$ Million), 2021–2026
        7.9.5 Genscript Probio Recent Developments
    7.10 Novoprotein
        7.10.1 Novoprotein Profile
        7.10.2 Novoprotein Main Business
        7.10.3 Novoprotein mRNA Vaccine Drugs Development Services Products, Services, and Solutions
        7.10.4 Novoprotein mRNA Vaccine Drugs Development Services Revenue (US$ Million), 2021–2026
        7.10.5 Novoprotein Recent Developments
    7.11 Porton Advanced Solutions
        7.11.1 Porton Advanced Solutions Profile
        7.11.2 Porton Advanced Solutions Main Business
        7.11.3 Porton Advanced Solutions mRNA Vaccine Drugs Development Services Products, Services, and Solutions
        7.11.4 Porton Advanced Solutions mRNA Vaccine Drugs Development Services Revenue (US$ Million), 2021–2026
        7.11.5 Porton Advanced Solutions Recent Developments
    7.12 Precision NanoSystems
        7.12.1 Precision NanoSystems Profile
        7.12.2 Precision NanoSystems Main Business
        7.12.3 Precision NanoSystems mRNA Vaccine Drugs Development Services Products, Services, and Solutions
        7.12.4 Precision NanoSystems mRNA Vaccine Drugs Development Services Revenue (US$ Million), 2021–2026
        7.12.5 Precision NanoSystems Recent Developments

8 Industry Chain Analysis
    8.1 mRNA Vaccine Drugs Development Services Value Chain
    8.2 mRNA Vaccine Drugs Development Services Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Key Suppliers of Raw Materials
        8.2.3 Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream (Customer) Analysis
    8.5 Sales Model and Sales Channelss
        8.5.1 mRNA Vaccine Drugs Development Services Sales Model
        8.5.2 Sales Channels
        8.5.3 mRNA Vaccine Drugs Development Services Distributors

9 Research Findings and Conclusion

10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
            10.1.1.1 Research Programs/Design
            10.1.1.2 Market Size Estimation
            10.1.1.3 Market Breakdown and Data Triangulation
        10.1.2 Data Source
            10.1.2.1 Secondary Sources
            10.1.2.2 Primary Sources
    10.2 Author Details
    10.3 Disclaimer

Table of Figures

List of Tables
Table 1. mRNA Vaccine Drugs Development Services Market Trends
Table 2. mRNA Vaccine Drugs Development Services Market Drivers & Opportunities
Table 3. mRNA Vaccine Drugs Development Services Market Challenges
Table 4. mRNA Vaccine Drugs Development Services Market Restraints
Table 5. Global mRNA Vaccine Drugs Development Services Revenue by Company (US$ Million), 2021–2026
Table 6. Global mRNA Vaccine Drugs Development Services Revenue Market Share by Company (2021–2026)
Table 7. Key Companies’ R&D and Operations Footprint and Headquarters
Table 8. Key Companies mRNA Vaccine Drugs Development Services Product Type
Table 9. Key Companies General Availability (GA) Timeline for mRNA Vaccine Drugs Development Services
Table 10. Global mRNA Vaccine Drugs Development Services Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Companies by Tier (Tier 1, Tier 2, Tier 3), based on mRNA Vaccine Drugs Development Services revenue, 2025
Table 12. Mergers & Acquisitions and Expansion Plans
Table 13. Global mRNA Vaccine Drugs Development Services Sales Value by Type: 2021 vs 2025 vs 2032 (US$ Million)
Table 14. Global mRNA Vaccine Drugs Development Services Sales Value by Type (US$ Million), 2021–2026
Table 15. Global mRNA Vaccine Drugs Development Services Sales Value by Type (US$ Million), 2027–2032
Table 16. Global mRNA Vaccine Drugs Development Services Sales Market Share in Value by Type (2021–2026)
Table 17. Global mRNA Vaccine Drugs Development Services Sales Market Share in Value by Type (2027–2032)
Table 18. Global mRNA Vaccine Drugs Development Services Sales Value by Application: 2021 vs 2025 vs 2032 (US$ Million)
Table 19. Global mRNA Vaccine Drugs Development Services Sales Value by Application (US$ Million), 2021–2026
Table 20. Global mRNA Vaccine Drugs Development Services Sales Value by Application (US$ Million), 2027–2032
Table 21. Global mRNA Vaccine Drugs Development Services Sales Market Share in Value by Application (2021–2026)
Table 22. Global mRNA Vaccine Drugs Development Services Sales Market Share in Value by Application (2027–2032)
Table 23. Global mRNA Vaccine Drugs Development Services Sales Value by Region, (US$ Million), 2021 vs 2025 vs 2032
Table 24. Global mRNA Vaccine Drugs Development Services Sales Value by Region (US$ Million), 2021–2026
Table 25. Global mRNA Vaccine Drugs Development Services Sales Value by Region (US$ Million), 2027–2032
Table 26. Global mRNA Vaccine Drugs Development Services Sales Value by Region (%), 2021–2026
Table 27. Global mRNA Vaccine Drugs Development Services Sales Value by Region (%), 2027–2032
Table 28. Key Countries/Regions mRNA Vaccine Drugs Development Services Sales Value Growth Trends, (US$ Million): 2021 vs 2025 vs 2032
Table 29. Key Countries/Regions mRNA Vaccine Drugs Development Services Sales Value, (US$ Million), 2021–2026
Table 30. Key Countries/Regions mRNA Vaccine Drugs Development Services Sales Value, (US$ Million), 2027–2032
Table 31. ReciBioPharm Basic Information List
Table 32. ReciBioPharm Description and Business Overview
Table 33. ReciBioPharm mRNA Vaccine Drugs Development Services Products, Services, and Solutions
Table 34. Revenue (US$ Million) in mRNA Vaccine Drugs Development Services Business of ReciBioPharm (2021–2026)
Table 35. ReciBioPharm Recent Developments
Table 36. Merck Basic Information List
Table 37. Merck Description and Business Overview
Table 38. Merck mRNA Vaccine Drugs Development Services Products, Services, and Solutions
Table 39. Revenue (US$ Million) in mRNA Vaccine Drugs Development Services Business of Merck (2021–2026)
Table 40. Merck Recent Developments
Table 41. Samsung Biologics Basic Information List
Table 42. Samsung Biologics Description and Business Overview
Table 43. Samsung Biologics mRNA Vaccine Drugs Development Services Products, Services, and Solutions
Table 44. Revenue (US$ Million) in mRNA Vaccine Drugs Development Services Business of Samsung Biologics (2021–2026)
Table 45. Samsung Biologics Recent Developments
Table 46. Thermo Fisher Scientific Basic Information List
Table 47. Thermo Fisher Scientific Description and Business Overview
Table 48. Thermo Fisher Scientific mRNA Vaccine Drugs Development Services Products, Services, and Solutions
Table 49. Revenue (US$ Million) in mRNA Vaccine Drugs Development Services Business of Thermo Fisher Scientific (2021–2026)
Table 50. Thermo Fisher Scientific Recent Developments
Table 51. Lonza Basic Information List
Table 52. Lonza Description and Business Overview
Table 53. Lonza mRNA Vaccine Drugs Development Services Products, Services, and Solutions
Table 54. Revenue (US$ Million) in mRNA Vaccine Drugs Development Services Business of Lonza (2021–2026)
Table 55. Lonza Recent Developments
Table 56. Ricoh Group Basic Information List
Table 57. Ricoh Group Description and Business Overview
Table 58. Ricoh Group mRNA Vaccine Drugs Development Services Products, Services, and Solutions
Table 59. Revenue (US$ Million) in mRNA Vaccine Drugs Development Services Business of Ricoh Group (2021–2026)
Table 60. Ricoh Group Recent Developments
Table 61. Aldevron Basic Information List
Table 62. Aldevron Description and Business Overview
Table 63. Aldevron mRNA Vaccine Drugs Development Services Products, Services, and Solutions
Table 64. Revenue (US$ Million) in mRNA Vaccine Drugs Development Services Business of Aldevron (2021–2026)
Table 65. Aldevron Recent Developments
Table 66. Wuxi Biologics Basic Information List
Table 67. Wuxi Biologics Description and Business Overview
Table 68. Wuxi Biologics mRNA Vaccine Drugs Development Services Products, Services, and Solutions
Table 69. Revenue (US$ Million) in mRNA Vaccine Drugs Development Services Business of Wuxi Biologics (2021–2026)
Table 70. Wuxi Biologics Recent Developments
Table 71. Genscript Probio Basic Information List
Table 72. Genscript Probio Description and Business Overview
Table 73. Genscript Probio mRNA Vaccine Drugs Development Services Products, Services, and Solutions
Table 74. Revenue (US$ Million) in mRNA Vaccine Drugs Development Services Business of Genscript Probio (2021–2026)
Table 75. Genscript Probio Recent Developments
Table 76. Novoprotein Basic Information List
Table 77. Novoprotein Description and Business Overview
Table 78. Novoprotein mRNA Vaccine Drugs Development Services Products, Services, and Solutions
Table 79. Revenue (US$ Million) in mRNA Vaccine Drugs Development Services Business of Novoprotein (2021–2026)
Table 80. Novoprotein Recent Developments
Table 81. Porton Advanced Solutions Basic Information List
Table 82. Porton Advanced Solutions Description and Business Overview
Table 83. Porton Advanced Solutions mRNA Vaccine Drugs Development Services Products, Services, and Solutions
Table 84. Revenue (US$ Million) in mRNA Vaccine Drugs Development Services Business of Porton Advanced Solutions (2021–2026)
Table 85. Porton Advanced Solutions Recent Developments
Table 86. Precision NanoSystems Basic Information List
Table 87. Precision NanoSystems Description and Business Overview
Table 88. Precision NanoSystems mRNA Vaccine Drugs Development Services Products, Services, and Solutions
Table 89. Revenue (US$ Million) in mRNA Vaccine Drugs Development Services Business of Precision NanoSystems (2021–2026)
Table 90. Precision NanoSystems Recent Developments
Table 91. Revenue (US$ Million) in mRNA Vaccine Drugs Development Services Business of Company 40 (2021–2026)
Table 92. Company 40 Recent Developments
Table 93. Key Raw Materials Lists
Table 94. Key Suppliers of Raw Materials Lists
Table 95. mRNA Vaccine Drugs Development Services Downstream Customers
Table 96. mRNA Vaccine Drugs Development Services Distributors List
Table 97. Research Programs/Design for This Report
Table 98. Key Data Information from Secondary Sources
Table 99. Key Data Information from Primary Sources

List of Figures
Figure 1. mRNA Vaccine Drugs Development Services Product Picture
Figure 2. Global mRNA Vaccine Drugs Development Services Sales Value, 2021 vs 2025 vs 2032 (US$ Million)
Figure 3. Global mRNA Vaccine Drugs Development Services Sales Value (US$ Million), 2021–2032
Figure 4. mRNA Vaccine Drugs Development Services Report Years Considered
Figure 5. Global mRNA Vaccine Drugs Development Services Players Revenue Ranking (US$ Million), 2025
Figure 6. The 5 and 10 Largest Companies in the World: Market Share by mRNA Vaccine Drugs Development Services Revenue in 2025
Figure 7. mRNA Vaccine Drugs Development Services Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 8. mRNA Process Development Services Picture
Figure 9. mRNA Synthesis Services Picture
Figure 10. mRNA Drug Substance Purification Services Picture
Figure 11. Others Picture
Figure 12. Global mRNA Vaccine Drugs Development Services Sales Value by Type (US$ Million), 2021 vs 2025 vs 2032
Figure 13. Global mRNA Vaccine Drugs Development Services Sales Value Market Share by Type, 2025 & 2032
Figure 14. Product Picture of Non-Replicating mRNA Vaccine Drugs
Figure 15. Product Picture of Self-Amplifying mRNA Vaccine Drugs
Figure 16. Global mRNA Vaccine Drugs Development Services Sales Value by Application (US$ Million), 2021 vs 2025 vs 2032
Figure 17. Global mRNA Vaccine Drugs Development Services Sales Value Market Share by Application, 2025 & 2032
Figure 18. North America mRNA Vaccine Drugs Development Services Sales Value (US$ Million), 2021–2032
Figure 19. North America mRNA Vaccine Drugs Development Services Sales Value by Country (%), 2025 vs 2032
Figure 20. Europe mRNA Vaccine Drugs Development Services Sales Value (US$ Million), 2021–2032
Figure 21. Europe mRNA Vaccine Drugs Development Services Sales Value by Country (%), 2025 vs 2032
Figure 22. Asia Pacific mRNA Vaccine Drugs Development Services Sales Value (US$ Million), 2021–2032
Figure 23. Asia Pacific mRNA Vaccine Drugs Development Services Sales Value by Subregion (%), 2025 vs 2032
Figure 24. South America mRNA Vaccine Drugs Development Services Sales Value (US$ Million), 2021–2032
Figure 25. South America mRNA Vaccine Drugs Development Services Sales Value by Country (%), 2025 vs 2032
Figure 26. Middle East & Africa mRNA Vaccine Drugs Development Services Sales Value (US$ Million), 2021–2032
Figure 27. Middle East & Africa mRNA Vaccine Drugs Development Services Sales Value by Country (%), 2025 vs 2032
Figure 28. Key Countries/Regions mRNA Vaccine Drugs Development Services Sales Value (%), 2021–2032
Figure 29. United States mRNA Vaccine Drugs Development Services Sales Value (US$ Million), 2021–2032
Figure 30. United States mRNA Vaccine Drugs Development Services Sales Value by Type (%), 2025 vs 2032
Figure 31. United States mRNA Vaccine Drugs Development Services Sales Value by Application (%), 2025 vs 2032
Figure 32. Europe mRNA Vaccine Drugs Development Services Sales Value (US$ Million), 2021–2032
Figure 33. Europe mRNA Vaccine Drugs Development Services Sales Value by Type (%), 2025 vs 2032
Figure 34. Europe mRNA Vaccine Drugs Development Services Sales Value by Application (%), 2025 vs 2032
Figure 35. China mRNA Vaccine Drugs Development Services Sales Value (US$ Million), 2021–2032
Figure 36. China mRNA Vaccine Drugs Development Services Sales Value by Type (%), 2025 vs 2032
Figure 37. China mRNA Vaccine Drugs Development Services Sales Value by Application (%), 2025 vs 2032
Figure 38. Japan mRNA Vaccine Drugs Development Services Sales Value (US$ Million), 2021–2032
Figure 39. Japan mRNA Vaccine Drugs Development Services Sales Value by Type (%), 2025 vs 2032
Figure 40. Japan mRNA Vaccine Drugs Development Services Sales Value by Application (%), 2025 vs 2032
Figure 41. South Korea mRNA Vaccine Drugs Development Services Sales Value (US$ Million), 2021–2032
Figure 42. South Korea mRNA Vaccine Drugs Development Services Sales Value by Type (%), 2025 vs 2032
Figure 43. South Korea mRNA Vaccine Drugs Development Services Sales Value by Application (%), 2025 vs 2032
Figure 44. Southeast Asia mRNA Vaccine Drugs Development Services Sales Value (US$ Million), 2021–2032
Figure 45. Southeast Asia mRNA Vaccine Drugs Development Services Sales Value by Type (%), 2025 vs 2032
Figure 46. Southeast Asia mRNA Vaccine Drugs Development Services Sales Value by Application (%), 2025 vs 2032
Figure 47. India mRNA Vaccine Drugs Development Services Sales Value (US$ Million), 2021–2032
Figure 48. India mRNA Vaccine Drugs Development Services Sales Value by Type (%), 2025 vs 2032
Figure 49. India mRNA Vaccine Drugs Development Services Sales Value by Application (%), 2025 vs 2032
Figure 50. mRNA Vaccine Drugs Development Services Value Chain
Figure 51. mRNA Vaccine Drugs Development Services Cost Structure
Figure 52. Channels of Distribution (Direct Sales, and Distribution)
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Figure 55. Key Executives Interviewed

お見積>

サンプルお申込み>

今すぐ購入>

PDFダウンロード>

当社から購入のメリット

購入方法

※当サイトに掲載されていない海外調査報告書も当社経由でご購入いただけますので、お問い合わせください。

※市場調査レポートの購入や市場調査をご希望の場合は、実績と信頼のある株式会社市場調査センターにお任せください。

*フォーチュン500企業は当社と緊密な協力関係を確立しています

クライアント様（例）